![](https://medcitynews.com/uploads/2021/07/GettyImages-1280895783-150x150.jpg)
The Binding Site
-
Thermo Fisher bets big on blood cancer, immune diagnostics with $2.6B Binding Site buyout
Thermo Fisher Scientific’s acquisition of The Binding Site brings a company that specializes in diagnostic tests for blood cancers and immune system disorders. It’s Thermo Fisher’s biggest acquisition since its 2021 buyout of contract research organization PPD.